Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma

被引：42
|
作者：
Mehta, Anurag [1 ]
Gupta, Arjun [1 ]
Hannallah, Franck [1 ]
Koshy, Thomas [2 ]
Reimold, Sharon [2 ]
机构：
[1] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Cardiol, Dallas, TX 75390 USA
来源：
MELANOMA RESEARCH | 2016年 / 26卷 / 03期
关键词：
D O I：
10.1097/CMR.0000000000000251
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：319 / 320
页数：2
相关论文
共 50 条
  • [21] A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab
    Olson, Daniel J.
    Rajagopal, Padma
    Tjota, Melissa Y.
    Venkataraman, Girish
    Luke, Jason J.
    Gajewski, Thomas F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [22] FDG PET in the evaluation of immune-related hypophysitis and thyroiditis following combination ipilimumab and nivolumab in advanced melanoma
    Iravani, Amir
    Galligan, Anna
    Lasocki, Arian
    Wallace, Roslyn
    Weppler, Alison
    Yeung, George Au
    Akhurst, Tim
    Sachithanandan, Nirupa
    Chiang, Cherie
    Sandhu, Shahneen
    Hicks, Rodney
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [23] Extragenital lichen sclerosus is an immune-related adverse event with nivolumab
    Williams, E.
    Mackool, B.
    Nazarian, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S141 - S141
  • [24] Nivolumab-induced Pancreatitis: An Immune-related Adverse Event
    Saito, Hiroaki
    Ono, Kana
    RADIOLOGY, 2019, 293 (03) : 521 - 521
  • [25] Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
    Freeman-Keller, Morganna
    Kim, Youngchul
    Cronin, Heather
    Richards, Allison
    Gibney, Geoffrey
    Weber, Jeffrey S.
    CLINICAL CANCER RESEARCH, 2016, 22 (04) : 886 - 894
  • [26] Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Ikeda, Takashi
    Ishihara, Hiroki
    Nemoto, Yuki
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Takagi, Toshio
    Iizuka, Junpei
    Hashimoto, Yasunobu
    Ishida, Hideki
    Kondo, Tsunenori
    Tanabe, Kazunari
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) : 735.e9 - 735.e16
  • [27] Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report
    Kai Johnson
    Majd Issa
    Anish Parikh
    Paul Monk
    Ming Yin
    Amir Mortazavi
    Yuanquan Yang
    BMC Urology, 21
  • [28] Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report
    Johnson, Kai
    Issa, Majd
    Parikh, Anish
    Monk, Paul
    Yin, Ming
    Mortazavi, Amir
    Yang, Yuanquan
    BMC UROLOGY, 2021, 21 (01)
  • [29] EBV-aggravated Colitis as a Side Effect of Immune Combination Therapy with Nivolumab and Ipilimumab for metastatic Melanoma
    Kruse, L.
    Kosova, K.
    Bohne, A. S.
    Weichenthal, M.
    Kaehler, K. C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 16 - 17
  • [30] Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma
    Weber, Jeffrey S.
    Puranik, Amrutesh
    Mitzutani, Teruyuki
    Muramatsu, Tomoaki
    Goldberg, Judith D.
    Mehnert, Janice M.
    Li, Xiaochun
    Levinson, Benjamin A.
    Hamid, Omid
    Mehmi, Inderjit
    Faries, Mark B.
    Hodi, F. Stephen
    Buchbinder, Elizabeth Iannotti
    Ott, Patrick Alexander
    Bajwa, Sofia
    Arriola, Perla
    Legros, Naika
    Sullivan, Ryan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345